- Home
- GECC vs OTLK Comparison
GECC vs OTLK Comparison
Compare GECC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | OTLK |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 119.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GECC | OTLK |
|---|---|---|
| Price | $7.03 | $1.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.75 | $4.67 |
| AVG Volume (30 Days) | 122.6K | ★ 4.2M |
| Earning Date | 11-04-2025 | 02-13-2026 |
| Dividend Yield | ★ 21.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,553,000.00 | $1,413,535.00 |
| Revenue This Year | $32.16 | $2,048.59 |
| Revenue Next Year | $3.26 | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.68 | N/A |
| 52 Week Low | $6.61 | $0.79 |
| 52 Week High | $11.46 | $3.39 |
Technical Indicators
Market Signals| Indicator | GECC | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 39.72 |
| Support Level | $6.61 | $1.78 |
| Resistance Level | $6.94 | $2.03 |
| Average True Range (ATR) | 0.27 | 0.25 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 31.31 | 6.39 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.